Keros Therapeutics, Inc. Preferred Stock Dividends, Income Statement Impact
Keros Therapeutics, Inc. (KROS) reported Preferred Stock Dividends, Income Statement Impact of $0 for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2021-11-04
- Keros Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2021-09-30 was $0.00.
- Keros Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2021-03-31 was $0.00, a 100.00% decline year-over-year.
- Keros Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2020-12-31 was -$1.01M.
- Keros Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Keros Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2019 was $1.80M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2021-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | -$1.01M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | -$1.01M derived: sum of 3 quarters · filed 2021-08-05 | -$1.01M derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | -$1.01M derived: sum of 2 quarters · filed 2021-05-06 | -$1.01M derived: sum of 3 quarters · filed 2021-11-04 | -$806.00K derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-12-31 | -$1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | -$1.01M derived: sum of 2 quarters · filed 2021-11-04 | -$806.00K derived: sum of 3 quarters · filed 2021-11-04 | $0.00 10-K · filed 2021-03-25 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $206.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.01M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $206.00K 10-Q · filed 2021-08-05 | $1.01M 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $806.00K 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | $1.80M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |